У нас вы можете посмотреть бесплатно Eczema: What Next After Dupixent Failure? или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
If you're one of the many eczema patients who has tried Dupixent without achieving satisfactory relief, this video is for you. Dupixent is often portrayed as the ultimate solution for moderate to severe atopic dermatitis, but what happens when it fails to control your symptoms adequately? In this comprehensive guide, we'll explore the reasons behind Dupixent's ineffectiveness for some patients and delve into the various options available to regain control over your eczema. From ruling out potential misdiagnoses or coexisting skin conditions to combination therapies with topical steroids, phototherapy, or other immunomodulatory drugs, we'll cover a range of approaches backed by recent studies. Additionally, we'll introduce you to the exciting new class of JAK-STAT inhibitors, including medications like Cibinqo, Opzelura, and Rinvoq, which offer promising alternatives for eczema management. Whether you're seeking relief from severe itching, sleepless nights, or a general improvement in your quality of life, this video will provide you with valuable insights and actionable steps to take control of your eczema journey beyond Dupixent. Join us as we navigate the complexities of this condition and empower you with the knowledge to find the right solution for your unique needs. For more information , please see the following resources: Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. https://www.jaad.org/action/showPdf?p... Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis https://www.nejm.org/doi/pdf/10.1056/... Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)* https://www.ncbi.nlm.nih.gov/pmc/arti... JAK Inhibitors for Atopic Dermatitis https://www.webmd.com/skin-problems-a... Clinical Challenges: Is Recalcitrant Atopic Dermatitis Really Comorbid Disease? https://www.medpagetoday.com/clinical... Difficult to control atopic dermatitis https://www.ncbi.nlm.nih.gov/pmc/arti... GUIDELINES OF CARE FOR THE MANAGEMENT OF ATOPIC DERMATITIS: https://www.ncbi.nlm.nih.gov/pmc/arti...